SDC1 and Miyoshi myopathy: Gene expression profiling (GEP) of CD138+ plasma cells has further described the molecular heterogeneity in MM and can reliably subdivide MM into distinct molecular subtypes.8, 16, 17 Using this technology it is also possible to risk stratify MM and identify 15% of presenting cases with a very poor prognosis.